BTIG raised the firm’s price target on Edwards Lifesciences (EW) to $100 from $98 and keeps a Buy rating on the shares. The firm is citing the company’s better-than-expected Q1 results and confident outlook, supported by share gains and procedure momentum, the analyst tells investors in a research note. Management also reiterated its long-term targets of 10% annual sales growth and 50-100 bps of annual operating margin expansion in 2027 and beyond, BTIG added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $85 from $87 at Canaccord
- Edwards Lifesciences price target raised to $87 from $85 at Baird
- Edwards Lifesciences price target lowered to $100 from $103 at BofA
- Closing Bell Movers: Intel jumps 19% on blowout earnings
- Edwards Lifesciences sees Q2 EPS 70c-76c, consensus 75c